Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Navigate Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Provides Shareholder Update

December 15, 2022

UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

December 12, 2022

Titan Pharmaceuticals Announces Board Expansion and Management Changes

August 16, 2022

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

July 5, 2022

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

February 2, 2022

Titan Pharmaceuticals to Explore Strategic Alternatives

December 21, 2021

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

November 8, 2021

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

November 5, 2021

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

October 25, 2021

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

October 12, 2021

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...24
  • Next »
© 2023 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter